List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1066391/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature, 2003, 423, 762-769.	13.7	2,804
2	Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. Journal of Clinical Investigation, 2006, 116, 1784-1792.	3.9	2,339
3	Adiponectin and Adiponectin Receptors. Endocrine Reviews, 2005, 26, 439-451.	8.9	2,215
4	Diabetes in Asia. JAMA - Journal of the American Medical Association, 2009, 301, 2129.	3.8	1,674
5	PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin Resistance. Molecular Cell, 1999, 4, 597-609.	4.5	1,281
6	Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Journal of Diabetes Investigation, 2010, 1, 212-228.	1.1	1,206
7	Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nature Medicine, 2007, 13, 332-339.	15.2	1,177
8	Disruption of Adiponectin Causes Insulin Resistance and Neointimal Formation. Journal of Biological Chemistry, 2002, 277, 25863-25866.	1.6	1,149
9	Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature, 1994, 372, 182-186.	13.7	988
10	Impaired Multimerization of Human Adiponectin Mutants Associated with Diabetes. Journal of Biological Chemistry, 2003, 278, 40352-40363.	1.6	871
11	Adiponectin and AdipoR1 regulate PGC-1α and mitochondria by Ca2+ and AMPK/SIRT1. Nature, 2010, 464, 1313-1319.	13.7	859
12	Globular Adiponectin Protected ob/ob Mice from Diabetes and ApoE-deficient Mice from Atherosclerosis. Journal of Biological Chemistry, 2003, 278, 2461-2468.	1.6	783
13	Overexpression of Monocyte Chemoattractant Protein-1 in Adipose Tissues Causes Macrophage Recruitment and Insulin Resistance. Journal of Biological Chemistry, 2006, 281, 26602-26614.	1.6	746
14	PPAR Î ³ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. Journal of Clinical Investigation, 2004, 113, 846-855.	3.9	701
15	SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nature Genetics, 2008, 40, 1098-1102.	9.4	641
16	A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature, 2013, 503, 493-499.	13.7	565
17	A cross-population atlas of genetic associations for 220 human phenotypes. Nature Genetics, 2021, 53, 1415-1424.	9.4	560
18	Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians. Nature Genetics, 2012, 44, 67-72.	9.4	545

Τακαςμι Καdowaki

#	Article	IF	CITATIONS
19	PPAR Î ³ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. Journal of Clinical Investigation, 2004, 113, 846-855.	3.9	462
20	Increased insulin sensitivity and hypoglycaemia in mice lacking the p85α subunit of phosphoinositide 3–kinase. Nature Genetics, 1999, 21, 230-235.	9.4	374
21	Impaired Insulin Signaling in Endothelial Cells Reduces Insulin-Induced Glucose Uptake by Skeletal Muscle. Cell Metabolism, 2011, 13, 294-307.	7.2	362
22	Potential Role of Protein Kinase B in Insulin-induced Glucose Transport, Glycogen Synthesis, and Protein Synthesis. Journal of Biological Chemistry, 1998, 273, 5315-5322.	1.6	328
23	Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetology International, 2010, 1, 2-20.	0.7	322
24	Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet, The, 2019, 394, 39-50.	6.3	315
25	Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases. Nature Genetics, 2020, 52, 669-679.	9.4	304
26	Identification of type 2 diabetes loci in 433,540 East Asian individuals. Nature, 2020, 582, 240-245.	13.7	282
27	Pioglitazone Ameliorates Insulin Resistance and Diabetes by Both Adiponectin-dependent and -independent Pathways. Journal of Biological Chemistry, 2006, 281, 8748-8755.	1.6	274
28	Adiponectin receptors: A review of their structure, function and how they work. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 15-23.	2.2	272
29	Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone. Nature, 1997, 390, 91-96.	13.7	268
30	Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nature Genetics, 2022, 54, 560-572.	9.4	250
31	A genome-wide association study in the Japanese population identifies susceptibility loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B. Nature Genetics, 2010, 42, 864-868.	9.4	245
32	Angiotensin II Partly Mediates Mechanical Stress–Induced Cardiac Hypertrophy. Circulation Research, 1995, 77, 258-265.	2.0	244
33	Adiponectin Enhances Insulin Sensitivity by Increasing Hepatic IRS-2 Expression via a Macrophage-Derived IL-6-Dependent Pathway. Cell Metabolism, 2011, 13, 401-412.	7.2	236
34	Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 951-964.	5.5	228
35	The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Letters, 2008, 582, 74-80.	1.3	224
36	Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease. Nature Genetics, 2017, 49, 1450-1457.	9.4	218

#	Article	IF	CITATIONS
37	IL-1α induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs. Journal of Cell Biology, 2015, 209, 453-466.	2.3	213
38	Insulin receptor substrate 2 plays a crucial role in \hat{I}^2 cells and the hypothalamus. Journal of Clinical Investigation, 2004, 114, 917-927.	3.9	209
39	Dynamic Functional Relay between Insulin Receptor Substrate 1 and 2 in Hepatic Insulin Signaling during Fasting and Feeding. Cell Metabolism, 2008, 8, 49-64.	7.2	204
40	Adipose Natural Regulatory B Cells Negatively Control Adipose Tissue Inflammation. Cell Metabolism, 2013, 18, 759-766.	7.2	195
41	Rho Family Small G Proteins Play Critical Roles in Mechanical Stress–Induced Hypertrophic Responses in Cardiac Myocytes. Circulation Research, 1999, 84, 458-466.	2.0	178
42	Crystal structures of the human adiponectin receptors. Nature, 2015, 520, 312-316.	13.7	176
43	DialBetics. Journal of Diabetes Science and Technology, 2014, 8, 209-215.	1.3	175
44	Molecular Mechanism of Insulin Resistance and Obesity. Experimental Biology and Medicine, 2003, 228, 1111-1117.	1.1	168
45	Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese population. Nature Genetics, 2019, 51, 379-386.	9.4	164
46	Genome-wide association study identifies three novel loci for type 2 diabetes. Human Molecular Genetics, 2014, 23, 239-246.	1.4	158
47	Involvement of p85 in p53-dependent apoptotic response to oxidative stress. Nature, 1998, 391, 707-710.	13.7	157
48	Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway. Biochemical and Biophysical Research Communications, 2009, 382, 51-56.	1.0	156
49	Genome-wide association studies in the Japanese population identify seven novel loci for type 2 diabetes. Nature Communications, 2016, 7, 10531.	5.8	149
50	Cell Type–Specific Angiotensin II–Evoked Signal Transduction Pathways. Circulation Research, 1998, 82, 337-345.	2.0	147
51	Usefulness of Measuring Both Body Mass Index and Waist Circumference for the Estimation of Visceral Adiposity and Related Cardiometabolic Risk Profile (from the INSPIRE ME IAA Study). American Journal of Cardiology, 2015, 115, 307-315.	0.7	141
52	Glycemic control, mortality, and hypoglycemia in critically ill patients: a systematic review and network meta-analysis of randomized controlled trials. Intensive Care Medicine, 2017, 43, 1-15.	3.9	139
53	Role of Insulin Resistance in MAFLD. International Journal of Molecular Sciences, 2021, 22, 4156.	1.8	131
54	Imbalanced Insulin Actions in Obesity and Type 2 Diabetes: Key Mouse Models of Insulin Signaling Pathway. Cell Metabolism, 2017, 25, 797-810.	7.2	124

#	Article	IF	CITATIONS
55	Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. Diabetes, Obesity and Metabolism, 2020, 22, 1607-1618.	2.2	118
56	Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice. Endocrinology, 2016, 157, 1029-1042.	1.4	116
57	The RNA Methyltransferase Complex of WTAP, METTL3, and METTL14 Regulates Mitotic Clonal Expansion in Adipogenesis. Molecular and Cellular Biology, 2018, 38, .	1.1	114
58	SREBP-1-independent regulation of lipogenic gene expression in adipocytes. Journal of Lipid Research, 2007, 48, 1581-1591.	2.0	111
59	Global Mapping of Cell Type–Specific Open Chromatin by FAIRE-seq Reveals the Regulatory Role of the NFI Family in Adipocyte Differentiation. PLoS Genetics, 2011, 7, e1002311.	1.5	103
60	Daytime Napping and the Risk of Cardiovascular Disease and All-Cause Mortality: A Prospective Study and Dose-Response Meta-Analysis. Sleep, 2015, 38, 1945-1953.	0.6	102
61	NAD ⁺ supplementation rejuvenates aged gut adult stem cells. Aging Cell, 2019, 18, e12935.	3.0	95
62	KLF15 Enables Rapid Switching between Lipogenesis and Gluconeogenesis during Fasting. Cell Reports, 2016, 16, 2373-2386.	2.9	94
63	Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes and Endocrinology,the, 2022, 10, 193-206.	5.5	90
64	Association of TCF7L2 polymorphisms with susceptibility to type 2 diabetes in 4,087 Japanese subjects. Journal of Human Genetics, 2008, 53, 174-180.	1.1	80
65	ENPP2 Contributes to Adipose Tissue Expansion and Insulin Resistance in Diet-Induced Obesity. Diabetes, 2014, 63, 4154-4164.	0.3	78
66	A Mutation in the Tyrosine Kinase Domain of the Insulin Receptor Associated with Insulin Resistance in an Obese Woman*. Journal of Clinical Endocrinology and Metabolism, 1991, 73, 894-901.	1.8	77
67	Differential hepatic distribution of insulin receptor substrates causes selective insulin resistance in diabetes and obesity. Nature Communications, 2016, 7, 12977.	5.8	77
68	Vascular Endothelial Growth Factor Induces Activation and Subcellular Translocation of Focal Adhesion Kinase (p125 FAK) in Cultured Rat Cardiac Myocytes. Circulation Research, 1999, 84, 1194-1202.	2.0	76
69	Differential effects of diet- and genetically-induced brain insulin resistance on amyloid pathology in a mouse model of Alzheimer's disease. Molecular Neurodegeneration, 2019, 14, 15.	4.4	74
70	Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial. Advances in Therapy, 2014, 31, 621-638.	1.3	73
71	NFIA co-localizes with PPARÎ ³ and transcriptionally controls the brown fat gene program. Nature Cell Biology, 2017, 19, 1081-1092.	4.6	73
72	Signal Transduction Mechanism of Insulin and Insulin-Like Growth Factor-1 Endocrine Journal, 1996, 43, S33-S41.	0.7	71

#	Article	IF	CITATIONS
73	Serum Levels of Vascular Endothelial Growth Factor in Patients with Acute Myocardial Infarction Undergoing Reperfusion Therapy. Clinical Science, 1997, 92, 453-454.	1.8	67
74	Sodiumâ€glucose coâ€transporterâ€2 inhibitors as addâ€on therapy to insulin for type 1 diabetes mellitus: Systematic review and metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2018, 20, 1755-1761.	2.2	66
75	Citrin/Mitochondrial Glycerol-3-phosphate Dehydrogenase Double Knock-out Mice Recapitulate Features of Human Citrin Deficiency. Journal of Biological Chemistry, 2007, 282, 25041-25052.	1.6	65
76	Dual Regulation of Gluconeogenesis by Insulin and Glucose in the Proximal Tubules of the Kidney. Diabetes, 2017, 66, 2339-2350.	0.3	61
77	Empagliflozin and kidney outcomes in Asian patients with typeÂ2 diabetes and established cardiovascular disease: Results from the EMPAâ€REG OUTCOME [®] trial. Journal of Diabetes Investigation, 2019, 10, 760-770.	1.1	61
78	Downregulation of macrophage Irs2 by hyperinsulinemia impairs IL-4-indeuced M2a-subtype macrophage activation in obesity. Nature Communications, 2018, 9, 4863.	5.8	60
79	Roles of Insulin Receptor Substrates in Insulin-Induced Stimulation of Renal Proximal Bicarbonate Absorption. Journal of the American Society of Nephrology: JASN, 2005, 16, 2288-2295.	3.0	59
80	Adiponectin/adiponectin receptor in disease and aging. Npj Aging and Mechanisms of Disease, 2015, 1, 15013.	4.5	59
81	Genome-Wide Association Meta-analysis Identifies Novel Variants Associated With Fasting Plasma Glucose in East Asians. Diabetes, 2015, 64, 291-298.	0.3	59
82	Adiponectin Receptor Signaling: A New Layer to the Current Model. Cell Metabolism, 2011, 13, 123-124.	7.2	57
83	<scp>l</scp> -cysteine reversibly inhibits glucose-induced biphasic insulin secretion and ATP production by inactivating PKM2. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1067-76.	3.3	57
84	Sirtuin1 Maintains Actin Cytoskeleton by Deacetylation of Cortactin in Injured Podocytes. Journal of the American Society of Nephrology: JASN, 2015, 26, 1939-1959.	3.0	56
85	The role of PPARÎ ³ in high-fat diet-induced obesity and insulin resistance. Journal of Diabetes and Its Complications, 2002, 16, 41-45.	1.2	55
86	Combating diabetes and obesity in Japan. Nature Medicine, 2006, 12, 73-74.	15.2	55
87	Growth Hormone-Induced Tyrosine Phosphorylation of EGF Receptor as an Essential Element Leading to MAP Kinase Activation and Gene Expression. Endocrine Journal, 1998, 45, S27-S31.	0.7	54
88	A Novel Low-Density Lipoprotein Receptor-Related Protein Mediating Cellular Uptake of Apolipoprotein E-Enriched β-VLDL in Vitroâ€,‡. Biochemistry, 2000, 39, 15817-15825.	1.2	53
89	Exenatide Exhibits Dose-Dependent Effects on Glycemic Control over 12 Weeks in Japanese Patients with Suboptimally Controlled Type 2 Diabetes. Endocrine Journal, 2009, 56, 415-424.	0.7	52
90	A qualitative study on the impact of internalized stigma on type 2 diabetes self-management. Patient Education and Counseling, 2016, 99, 1233-1239.	1.0	52

#	Article	IF	CITATIONS
91	Hepatic Sdf2l1 controls feeding-induced ER stress and regulates metabolism. Nature Communications, 2019, 10, 947.	5.8	52
92	Restored insulin-sensitivity in IRS-1–deficient mice treated by adenovirus-mediated gene therapy. Journal of Clinical Investigation, 2000, 105, 1437-1445.	3.9	52
93	J-curve relation between daytime nap duration and type 2 diabetes or metabolic syndrome: A dose-response meta-analysis. Scientific Reports, 2016, 6, 38075.	1.6	49
94	Genetic architecture of type 2 diabetes. Biochemical and Biophysical Research Communications, 2014, 452, 213-220.	1.0	48
95	A genome-wide association study identifies PLCL2 and AP3D1-DOT1L-SF3A2 as new susceptibility loci for myocardial infarction in Japanese. European Journal of Human Genetics, 2015, 23, 374-380.	1.4	48
96	New glycemic targets for patients with diabetes from the Japan Diabetes Society. Journal of Diabetes Investigation, 2017, 8, 123-125.	1.1	48
97	Perspective of Small-Molecule AdipoR Agonist for Type 2 Diabetes and Short Life in Obesity. Diabetes and Metabolism Journal, 2015, 39, 363.	1.8	47
98	Association between self-stigma and self-care behaviors in patients with type 2 diabetes: a cross-sectional study. BMJ Open Diabetes Research and Care, 2016, 4, e000156.	1.2	47
99	DialBetics With a Multimedia Food Recording Tool, FoodLog. Journal of Diabetes Science and Technology, 2015, 9, 534-540.	1.3	46
100	Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes. Kidney International, 2021, 99, 256-266.	2.6	46
101	Efficacy and safety of canagliflozin as addâ€on therapy to teneligliptin in <scp>J</scp> apanese patients with type 2 diabetes mellitus: <scp>R</scp> esults of a 24â€week, randomized, doubleâ€blind, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2017, 19, 874-882.	2.2	45
102	Vascular endothelial growth factor (VEGF) activates Raf-1, mitogen-activated protein (MAP) kinases, and S6 kinase (p90rsk) in cultured rat cardiac myocytes. Journal of Cellular Physiology, 1998, 175, 239-246.	2.0	44
103	Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type $\widehat{e}f2$ diabetes over $24\widehat{a}\in f$ weeks. Journal of Diabetes Investigation, 2011, 2, 210-217.	1.1	44
104	Blockade of class IB phosphoinositide-3 kinase ameliorates obesity-induced inflammation and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 5753-5758.	3.3	44
105	Fastâ€acting insulin aspart versus insulin aspart in the setting of insulin degludecâ€treated type 1 diabetes: Efficacy and safety from a randomized doubleâ€blind trial. Diabetes, Obesity and Metabolism, 2018, 20, 2885-2893.	2.2	44
106	Retrospective nationwide study on the trends in firstâ€line antidiabetic medication for patients with type 2 diabetes in Japan. Journal of Diabetes Investigation, 2022, 13, 280-291.	1.1	44
107	Efficacy and Safety of Empagliflozin Monotherapy for 52 Weeks in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Parallel-Group Study. Advances in Therapy, 2015, 32, 306-318.	1.3	43
108	Adiponectin/AdipoR Research and Its Implications for Lifestyle-Related Diseases. Frontiers in Cardiovascular Medicine, 2019, 6, 116.	1.1	42

Τακαςμι Καdowaki

#	Article	IF	CITATIONS
109	The Mechanism of Insulin-induced Signal Transduction Mediated by the Insulin Receptor Substrate Family. Endocrine Journal, 1999, 46, S25-S34.	0.7	41
110	Obesity in Insulin Receptor Substrateâ€⊉–Deficient Mice: Disrupted Control of Arcuate Nucleus Neuropeptides. Obesity, 2004, 12, 878-885.	4.0	41
111	Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52Âweeks leads to improved glycemic control. Diabetology International, 2011, 2, 32-44.	0.7	39
112	High hemoglobin A1c levels within the nonâ€diabetic range are associated with the risk of all cancers. International Journal of Cancer, 2016, 138, 1741-1753.	2.3	39
113	Validity and applicability of a simple questionnaire for the estimation of total and domain-specific physical activity. Diabetology International, 2011, 2, 47-54.	0.7	37
114	Adiponectin and its receptors: implications for obesity-associated diseases and longevity. Lancet Diabetes and Endocrinology,the, 2014, 2, 8-9.	5.5	37
115	Adiponectin Enhances Antibacterial Activity of Hematopoietic Cells by Suppressing Bone Marrow Inflammation. Immunity, 2016, 44, 1422-1433.	6.6	37
116	Role of insulin receptor substrates in the progression of hepatocellular carcinoma. Scientific Reports, 2017, 7, 5387.	1.6	37
117	SnapShot: Insulin Signaling Pathways. Cell, 2012, 148, 624-624.e1.	13.5	35
118	Usage Patterns of GlucoNote, a Self-Management Smartphone App, Based on ResearchKit for Patients With Type 2 Diabetes and Prediabetes. JMIR MHealth and UHealth, 2019, 7, e13204.	1.8	35
119	Adiponectin Enhances Quiescence Exit of Murine Hematopoietic Stem Cells and Hematopoietic Recovery Through mTORC1 Potentiation. Stem Cells, 2017, 35, 1835-1848.	1.4	34
120	Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. Nature Communications, 2020, 11, 3175.	5.8	34
121	Association between tear and blood glucose concentrations: Random intercept model adjusted with confounders in tear samples negative for occult blood. Journal of Diabetes Investigation, 2021, 12, 266-276.	1.1	34
122	Insulin Receptor Substrate-2 (Irs2) in Endothelial Cells Plays a Crucial Role in Insulin Secretion. Diabetes, 2015, 64, 876-886.	0.3	33
123	Testing the Feasibility and Usability of a Novel Smartphone-Based Self-Management Support System for Dialysis Patients: A Pilot Study. JMIR Research Protocols, 2017, 6, e63.	0.5	33
124	Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies. Expert Opinion on Pharmacotherapy, 2015, 16, 971-981.	0.9	32
125	Psychological and behavioural patterns of stigma among patients with type 2 diabetes: a cross-sectional study. BMJ Open, 2017, 7, e013425.	0.8	32
126	Germ-Line Contribution of Embryonic Stem Cells in Chimeric Mice: Influence of Karyotype and In Vitro Differentiation Ability Experimental Animals, 1997, 46, 17-23.	0.7	31

#	Article	IF	CITATIONS
127	Echinomycin inhibits adipogenesis in 3T3-L1 cells in a HIF-independent manner. Scientific Reports, 2017, 7, 6516.	1.6	31
128	Metabolomic analysis reveals hepatic metabolite perturbations in citrin/mitochondrial glycerol-3-phosphate dehydrogenase double-knockout mice, a model of human citrin deficiency. Molecular Genetics and Metabolism, 2011, 104, 492-500.	0.5	30
129	A variant within the FTO confers susceptibility to diabetic nephropathy in Japanese patients with type 2 diabetes. PLoS ONE, 2018, 13, e0208654.	1.1	30
130	Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients. Journal of Gastroenterology, 2020, 55, 227-243.	2.3	29
131	Insulin- and Lipopolysaccharide-Mediated Signaling in Adipose Tissue Macrophages Regulates Postprandial Glycemia through Akt-mTOR Activation. Molecular Cell, 2020, 79, 43-53.e4.	4.5	29
132	Factors Associated With Callus in Patients with Diabetes, Focused on Plantar Shear Stress During Gait. Journal of Diabetes Science and Technology, 2016, 10, 1353-1359.	1.3	28
133	Structural Basis and Genotype–Phenotype Correlations of INSR Mutations Causing Severe Insulin Resistance. Diabetes, 2017, 66, 2713-2723.	0.3	28
134	Design of and rationale for the Japan Diabetes compREhensive database project based on an Advanced electronic Medical record System (J-DREAMS). Diabetology International, 2017, 8, 375-382.	0.7	28
135	Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, doubleâ€blind, placeboâ€controlled, parallelâ€group comparative study. Diabetes, Obesity and Metabolism, 2018, 20, 453-457.	2.2	28
136	Robust and highly efficient hiPSC generation from patient non-mobilized peripheral blood-derived CD34+ cells using the auto-erasable Sendai virus vector. Stem Cell Research and Therapy, 2019, 10, 185.	2.4	28
137	A Case of Diabetic Amyotrophy Associated with 3243 Mitochondrial tRNA(leu; UUR) Mutation and Successful Therapy with Coenzyme Q10 Endocrine Journal, 1995, 42, 141-145.	0.7	27
138	How self-stigma affects patient activation in persons with type 2 diabetes: a cross-sectional study. BMJ Open, 2020, 10, e034757.	0.8	27
139	Design of and rationale for the Japan Diabetes Optimal Integrated Treatment study for 3 major risk factors of cardiovascular diseases (J-DOIT3): a multicenter, open-label, randomized, parallel-group trial. BMJ Open Diabetes Research and Care, 2016, 4, e000123.	1.2	26
140	Hepatic IRS1 and ß-catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients. Journal of Gastroenterology, 2018, 53, 1261-1275.	2.3	25
141	Four Mutant Alleles of the Insulin Receptor Gene Associated with Genetic Syndromes of Extreme Insulin Resistance. Biochemical and Biophysical Research Communications, 1997, 237, 516-520.	1.0	24
142	Genetic variants in the calpain-10 gene and the development of type 2 diabetes in the Japanese population. Journal of Human Genetics, 2005, 50, 92-98.	1.1	23
143	Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy. Diabetology International, 2013, 4, 160-172.	0.7	23
144	Willingness of patients with diabetes to use an ICT-based self-management tool: a cross-sectional study. BMJ Open Diabetes Research and Care, 2017, 5, e000322.	1.2	23

#	Article	IF	CITATIONS
145	Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period. Expert Opinion on Pharmacotherapy, 2017, 18, 1291-1300.	0.9	23
146	Variation in process quality measures of diabetes care by region and institution in Japan during 2015–2016: An observational study of nationwide claims data. Diabetes Research and Clinical Practice, 2019, 155, 107750.	1.1	23
147	Effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on weight loss is partly mediated by liver-brain-adipose neurocircuitry. Biochemical and Biophysical Research Communications, 2017, 493, 40-45.	1.0	22
148	Subcellular Localization of Insulin Receptor Substrate Family Proteins Associated With Phosphatidylinositol 3-Kinase Activity and Alterations in Lipolysis in Primary Mouse Adipocytes From IRS-1 Null Mice. Diabetes, 2001, 50, 1455-1463.	0.3	21
149	Transancestral fine-mapping of four type 2 diabetes susceptibility loci highlights potential causal regulatory mechanisms. Human Molecular Genetics, 2016, 25, 2070-2081.	1.4	21
150	Biosimilar vs originator insulins: Systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2018, 20, 1787-1792.	2.2	21
151	Longâ€term safety and efficacy of canagliflozin as addâ€on therapy to teneligliptin inJapanese patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 77-84.	2.2	21
152	Effects of supplementation on food intake, body weight and hepatic metabolites in the citrin/mitochondrial glycerol-3-phosphate dehydrogenase double-knockout mouse model of human citrin deficiency. Molecular Genetics and Metabolism, 2012, 107, 322-329.	0.5	20
153	NFIA differentially controls adipogenic and myogenic gene program through distinct pathways to ensure brown and beige adipocyte differentiation. PLoS Genetics, 2020, 16, e1009044.	1.5	20
154	AdipoR agonist increases insulin sensitivity and exercise endurance in AdipoR-humanized mice. Communications Biology, 2021, 4, 45.	2.0	20
155	Impact of COVID-19 pandemic on healthcare service use for non-COVID-19 patients in Japan: retrospective cohort study. BMJ Open, 2022, 12, e060390.	0.8	20
156	Potential Formula for the Calculation of Starting and Incremental Insulin Glargine Doses: ALOHA Subanalysis. PLoS ONE, 2012, 7, e41358.	1.1	19
157	Gastrointestinal symptom prevalence depends on disease duration and gastrointestinal region in type 2 diabetes mellitus. World Journal of Gastroenterology, 2017, 23, 6694-6704.	1.4	19
158	Antibody-mediated Insulin Resistance Treated by Cessation of Insulin Administration Internal Medicine, 2000, 39, 143-145.	0.3	18
159	DialBetics: Smartphone-Based Self-Management for Type 2 Diabetes Patients. Journal of Diabetes Science and Technology, 2012, 6, 983-985.	1.3	18
160	Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. Diabetes Care, 2022, 45, 1445-1452.	4.3	18
161	Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice. Diabetologia, 2016, 59, 2426-2434.	2.9	17
162	Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics and severity of renal impairment: A Japanese database analysis. Diabetes, Obesity and Metabolism, 2018, 20, 2830-2839.	2.2	17

#	Article	IF	CITATIONS
163	Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with TypeÂ2 Diabetes in Japan. Advances in Therapy, 2020, 37, 1065-1086.	1.3	17
164	Shear Stress-Normal Stress (Pressure) Ratio Decides Forming Callus in Patients with Diabetic Neuropathy. Journal of Diabetes Research, 2016, 2016, 1-10.	1.0	16
165	Previous dropout from diabetic care as a predictor of patients' willingness to use mobile applications for selfâ€management: A crossâ€sectional study. Journal of Diabetes Investigation, 2017, 8, 542-549.	1.1	16
166	Validating the use of photos to measure dietary intake: the method used by DialBetics, a smartphone-based self-management system for diabetes patients. Diabetology International, 2016, 7, 244-251.	0.7	15
167	A key role of nuclear factor Y in the refeeding response of fatty acid synthase in adipocytes. FEBS Letters, 2017, 591, 965-978.	1.3	15
168	Human adiponectin receptor AdipoR1 assumes closed and open structures. Communications Biology, 2020, 3, 446.	2.0	15
169	Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry). BMJ Open Diabetes Research and Care, 2021, 9, e001787.	1.2	15
170	Metabolic surgery in treatment of obese Japanese patients with type 2 diabetes: a joint consensus statement from the Japanese Society for Treatment of Obesity, the Japan Diabetes Society, and the Japan Society for the Study of Obesity. Diabetology International, 2022, 13, 1-30.	0.7	15
171	Expression, purification, crystallization, and preliminary X-ray crystallographic studies of the human adiponectin receptors, AdipoR1 and AdipoR2. Journal of Structural and Functional Genomics, 2015, 16, 11-23.	1.2	14
172	The association between health literacy levels and patient-reported outcomes in Japanese type 2 diabetic patients. SAGE Open Medicine, 2019, 7, 205031211986564.	0.7	14
173	A closer inspection of diabetes-related stigma: why more research is needed. Diabetology International, 2020, 11, 73-75.	0.7	14
174	Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placeboâ€controlled CARMELINA® trial. Diabetes, Obesity and Metabolism, 2020, 22, 1062-1073	2.2	14
175	Baseline predictive factors for glycemic control in Japanese type 2 diabetes patients treated with insulin glargine plus oral antidiabetic drugs: ALOHA study subanalysis. Diabetology International, 2013, 4, 16-22.	0.7	13
176	Glycemic control, mortality, secondary infection, and hypoglycemia in critically ill pediatric patients: a systematic review and network meta-analysis of randomized controlled trials. Intensive Care Medicine, 2017, 43, 1427-1429.	3.9	13
177	Oxidized albumin in blood reflects the severity of multiple vascular complications in diabetes mellitus. Metabolism Open, 2020, 6, 100032.	1.4	13
178	Genome-wide association studies identify two novel loci conferring susceptibility to diabetic retinopathy in Japanese patients with type 2 diabetes. Human Molecular Genetics, 2021, 30, 716-726.	1.4	13
179	Effectiveness and safety of basal supported oral therapy with insulin glargine, in Japanese insulin-naive, type 2 diabetes patients, with or without microvascular complications: subanalysis of the observational, non-interventional, 24-week follow-up Add-on Lantus® to Oral Hypoglycemic Acousts (ALOHA) study lournal of Diabetes and its Complications 2015, 20, 127, 122	1.2	12
180	Efficacy and safety of onceâ€daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26â€week, treatâ€toâ€target trial. Journal of Diabetes Investigation, 2016, 7, 711-717.	1.1	12

#	Article	IF	CITATIONS
181	Genes associated with diabetes: potential for novel therapeutic targets?. Expert Opinion on Therapeutic Targets, 2016, 20, 255-267.	1.5	12
182	CDK5 Regulatory Subunit-Associated Protein 1-like 1 Negatively Regulates Adipocyte Differentiation through Activation of Wnt Signaling Pathway. Scientific Reports, 2017, 7, 7326.	1.6	12
183	Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2018, 19, 83-91.	0.9	12
184	Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial. Diabetology International, 2021, 12, 87-100.	0.7	12
185	Long-term safety, tolerability, and efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetology International, 2011, 2, 94-105.	0.7	11
186	Replication study for the association of rs391300 in <i><scp>SRR</scp></i> and rs17584499 in <i><scp>PTPRD</scp></i> with susceptibility to type 2 diabetes in a <scp>J</scp> apanese population. Journal of Diabetes Investigation, 2013, 4, 168-173.	1.1	11
187	Structure and function analysis of adiponectin receptors toward development of novel antidiabetic agents promoting healthy longevity. Endocrine Journal, 2018, 65, 971-977.	0.7	11
188	Drug development research for novel adiponectin receptor-targeted antidiabetic drugs contributing to healthy longevity. Diabetology International, 2019, 10, 237-244.	0.7	11
189	LPL/AQP7/GPD2 promotes glycerol metabolism under hypoxia and prevents cardiac dysfunction during ischemia. FASEB Journal, 2021, 35, e22048.	0.2	11
190	Insulin receptor disorders in Japan. Diabetes Research and Clinical Practice, 1994, 24, S145-S151.	1.1	10
191	Oral aversion to dietary sugar, ethanol and glycerol correlates with alterations in specific hepatic metabolites in a mouse model of human citrin deficiency. Molecular Genetics and Metabolism, 2017, 120, 306-316.	0.5	10
192	Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance. Diabetes Therapy, 2018, 9, 1083-1097.	1.2	10
193	Effect of shortâ€ŧerm treatment with sitagliptin or glibenclamide on daily glucose fluctuation in drugâ€naÃīve Japanese patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2018, 20, 2274-2281.	2.2	10
194	Formation of distinct signalling complexes involving phosphatidylinositol 3-kinase activity with stimulation of epidermal growth factor or insulin-like growth factor-I in human skin fibroblasts. , 1999, 178, 69-75.		9
195	Establishment of a method of anonymization of DNA samples in genetic research. Journal of Human Genetics, 2003, 48, 327-330.	1.1	9
196	SnapShot: Physiology of Insulin Signaling. Cell, 2012, 148, 834-834.e1.	13.5	9
197	Mechanism for increased hepatic glycerol synthesis in the citrin/mitochondrial glycerol-3-phosphate dehydrogenase double-knockout mouse: Urine glycerol and glycerol 3-phosphate as potential diagnostic markers of human citrin deficiency. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 1787-1795.	1.8	9
198	Differential involvement of insulin receptor substrate (IRS)-1 and IRS-2 in brain insulin signaling is associated with the effects on amyloid pathology in a mouse model of Alzheimer's disease. Neurobiology of Disease, 2021, 159, 105510.	2.1	9

#	Article	IF	CITATIONS
199	A Japanese Case of Congenital Hyperinsulinism with Hyperammonemia Due to a Mutation in Glutamate Dehydrogenase (GLUD1) Gene Internal Medicine, 2001, 40, 32-37.	0.3	8
200	Maturity-onset Diabetes of the Young Resulting from a Novel Mutation in the HNF-4.ALPHA. Gene Internal Medicine, 2002, 41, 848-852.	0.3	8
201	Generation of Transgenic Mice on an NOD/SCID Background Using the Conventional Microinjection Technique. Biology of Reproduction, 2011, 84, 682-688.	1.2	8
202	DialBetics. Journal of Diabetes Science and Technology, 2016, 10, 804-805.	1.3	8
203	Pioglitazone Ameliorates Smooth Muscle Cell Proliferation in Cuff-Induced Neointimal Formation by Both Adiponectin-Dependent and -Independent Pathways. Scientific Reports, 2016, 6, 34707.	1.6	8
204	Pilot Study for the Development of a Self-Care System for Type 2 Diabetes Patients Using a Personal Digital Assistant (PDA). International Journal of Behavioral Medicine, 2016, 23, 295-299.	0.8	8
205	Thermographic findings in a case of type 2 diabetes with foot ulcer due to callus deterioration. Diabetology International, 2017, 8, 328-333.	0.7	8
206	Weekly Versus Daily Dipeptidyl Peptidase 4 Inhibitor Therapy for Type 2 Diabetes: Systematic Review and Meta-analysis. Diabetes Care, 2018, 41, e52-e55.	4.3	8
207	Pivotal role of inter-organ aspartate metabolism for treatment of mitochondrial aspartate-glutamate carrier 2 (citrin) deficiency, based on the mouse model. Scientific Reports, 2019, 9, 4179.	1.6	8
208	Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with TypeÂ2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan. Advances in Therapy, 2020, 37, 2477-2492.	1.3	8
209	Using mHealth to Provide Mobile App Users With Visualization of Health Checkup Data and Educational Videos on Lifestyle-Related Diseases: Methodological Framework for Content Development. JMIR MHealth and UHealth, 2020, 8, e20982.	1.8	8
210	Associations between diabetes duration and self-stigma development in Japanese people with type 2 diabetes: a secondary analysis of cross-sectional data. BMJ Open, 2021, 11, e055013.	0.8	8
211	Efficacy and Safety of Teneligliptin 40Âmg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies. Diabetes Therapy, 2018, 9, 623-636.	1.2	7
212	Diabetes and COVID-19: IDF perspective in the Western Pacific region. Diabetes Research and Clinical Practice, 2020, 166, 108278.	1.1	7
213	Factors associated with long-term care certification in older adults: a cross-sectional study based on a nationally representative survey in Japan. BMC Geriatrics, 2021, 21, 374.	1.1	7
214	New glycemic targets for patients with diabetes from the Japan Diabetes Society. Diabetology International, 2016, 7, 327-330.	0.7	6
215	Safety and efficacy of addition of sitagliptin to rapid-acting insulin secretagogues for glycemic control, including post-prandial hyperglycemia, among Japanese with type 2 diabetes mellitus. Diabetology International, 2016, 7, 155-166.	0.7	6
216	Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension. Expert Opinion on Pharmacotherapy, 2017, 18, 1903-1919.	0.9	6

#	Article	IF	CITATIONS
217	Insulin degludec in a simple or stepwise titration algorithm in a Japanese population of patients with type 2 diabetes: a randomized, 26-week, treat-to-target trial. Diabetology International, 2017, 8, 87-94.	0.7	6
218	Role of Hormone-sensitive Lipase in Leptin-Promoted Fat Loss and Glucose Lowering. Journal of Atherosclerosis and Thrombosis, 2017, 24, 1105-1116.	0.9	6
219	Novel and Simple Ultrasonographic Methods for Estimating the Abdominal Visceral Fat Area. International Journal of Endocrinology, 2017, 2017, 1-12.	0.6	6
220	Diabetes care providers' manual for disaster diabetes care. Diabetology International, 2019, 10, 153-179.	0.7	6
221	Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND): study design and baseline characteristics of patients with type 2 diabetes newly initiating oral antidiabetic drug monotherapy in Japan. BMJ Open Diabetes Research and Care, 2020, 8, e001361.	1.2	6
222	Association between nutritional guidance or ophthalmological examination and discontinuation of physician visits in patients with newly diagnosed diabetes: A retrospective cohort study using a nationwide database. Journal of Diabetes Investigation, 2021, 12, 1619-1631.	1.1	6
223	Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis. Expert Opinion on Drug Safety, 2021, 20, 1-14.	1.0	6
224	Efficacy of the Self-management Support System DialBetesPlus for Diabetic Kidney Disease: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2021, 10, e31061.	0.5	6
225	The Role of Phosphoinositide-3-kinase in Mast Cell Homing to the Gastrointestinal Tract. Novartis Foundation Symposium, 0, , 152-165.	1.2	6
226	Roles of Insulin Receptor Substrate-1 and Shc on Insulin-Like Growth Factor I Receptor Signaling in Early Passages of Cultured Human Fibroblasts. Endocrinology, 1997, 138, 741-750.	1.4	6
227	Stimulation of the phosphorylation of cytoskeletal 350-kDa and 300-kDa proteins by insulin-like growth factor-I, platelet-derived growth factor and phorbol ester in rat 3Y1 cells Cell Structure and Function, 1988, 13, 417-423.	0.5	6
228	Predictors for achieving target glycemic control in Japanese patients with type 2 diabetes after initiation of basal supported oral therapy using insulin glargine: sub-analysis of the ALOHA2 study, drug use surveillance in Japan. Diabetology International, 2016, 7, 188-198.	0.7	5
229	Diabetes Care Providers' Manual for Disaster Diabetes Care. Journal of Diabetes Investigation, 2019, 10, 1118-1142.	1.1	5
230	Outcomes of lactulose plus branchedâ€chain amino acid infusion and lactulose alone for hepatic encephalopathy: A retrospective cohort study using a national inpatient database. Hepatology Research, 2020, 50, 693-703.	1.8	5
231	Pseudoâ€hyperglucagonemia was observed in pancreatectomized patients when measured by glucagon sandwich enzymeâ€linked immunosorbent assay. Journal of Diabetes Investigation, 2021, 12, 286-289.	1.1	5
232	Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin. Diabetes, Obesity and Metabolism, 2021, 23, 2099-2108.	2.2	5
233	Structural basis of ethnic-specific variants of PAX4 associated with type 2 diabetes. Human Genome Variation, 2021, 8, 25.	0.4	5
234	Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry. BMJ Open, 2014, 4, e004760-e004760.	0.8	4

#	Article	IF	CITATIONS
235	Association between Washing Residue on the Feet and Tinea Pedis in Diabetic Patients. Nursing Research and Practice, 2015, 2015, 1-7.	0.4	4
236	Efficacy and safety assessment of basal supported oral therapy (BOT) with insulin glargine in a real-life clinical setting, stratified by concomitant orally administered antidiabetic agent (OAD) regimens including dipeptidyl peptidase-4 inhibitor (DPP-4i): subanalysis of the ALOHA2 study, drug-use surveillance in Japan. Diabetology International, 2016, 7, 299-307.	0.7	4
237	Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients. Advances in Therapy, 2018, 35, 817-831.	1.3	4
238	A randomized, placebo ontrolled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control. Diabetes, Obesity and Metabolism, 2021, 23, 1242-1251.	2.2	4
239	Clinical Characteristics and Incidences of Benign and Malignant Insulinoma Using a National Inpatient Database in Japan. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3477-3486.	1.8	4
240	A xanthene derivative, DS20060511, attenuates glucose intolerance by inducing skeletal muscle-specific GLUT4 translocation in mice. Communications Biology, 2021, 4, 994.	2.0	4
241	Potassium Concentration in Initial Fluid Therapy and In-Hospital Mortality of Patients with Diabetic Ketoacidosis. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2162-e2175.	1.8	4
242	Willingness of Patients Prescribed Medications for Lifestyle-Related Diseases to Use Personal Health Records: Questionnaire Study. Journal of Medical Internet Research, 2020, 22, e13866.	2.1	4
243	Severe aortic stenosis during leptin replacement therapy in a patient with generalized lipodystrophyâ€associated progeroid syndrome due to an <i>LMNA</i> variant: A case report. Journal of Diabetes Investigation, 2022, 13, 1636-1638.	1.1	4
244	Diabetes mellitus defined by hemoglobin A1c value: Risk characterization for incidence among Japanese subjects in the JPHC Diabetes Study. Journal of Diabetes Investigation, 2011, 2, 359-365.	1.1	3
245	Development of an Automatic Puncturing and Sampling System for a Self-Monitoring Blood Glucose Device. Diabetes Technology and Therapeutics, 2017, 19, 651-659.	2.4	3
246	Clinical usefulness of multigene screening with phenotype-driven bioinformatics analysis for the diagnosis of patients with monogenic diabetes or severe insulin resistance. Diabetes Research and Clinical Practice, 2020, 169, 108461.	1.1	3
247	Blood Glucose Control Strategy for Type 2 Diabetes Patients With COVID-19. Frontiers in Cardiovascular Medicine, 2020, 7, 593061.	1.1	3
248	Understanding the experiences of long-term maintenance of self-worth in persons with type 2 diabetes in Japan: a qualitative study. BMJ Open, 2020, 10, e034758.	0.8	3
249	Factors Associated with Callus Formation in the Plantar Region through Gait Measurement in Patients with Diabetic Neuropathy: An Observational Case-Control Study. Sensors, 2020, 20, 4863.	2.1	3
250	Clinical Features of Type B Insulin Resistance in Japanese Patients: Case Report and Survey-Based Case Series Study. Journal of Diabetes Research, 2020, 2020, 1-11.	1.0	3
251	Lack of Brain Insulin Receptor Substrate-1 Causes Growth Retardation, With Decreased Expression of Growth Hormone–Releasing Hormone in the Hypothalamus. Diabetes, 2021, 70, 1640-1653.	0.3	3
252	Fast and Accurate Ultrasonography for Visceral Fat Measurement. Lecture Notes in Computer Science, 2010, 13, 50-58.	1.0	3

#	Article	IF	CITATIONS
253	The sodiumâ€glucose coâ€transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoEâ€deficient mice with streptozotocinâ€induced diabetes. Pharmacology Research and Perspectives, 2022, 10, .	1.1	3
254	Familial Disorder with Increased Number of Insulin Receptors: A New Category of Insulin Receptor Abnormality*. Journal of Clinical Endocrinology and Metabolism, 1986, 63, 865-871.	1.8	2
255	Combined treatment with low-dose pioglitazone and beraprost sodium improves glucose intolerance without causing body weight gain. Diabetology International, 2013, 4, 226-232.	0.7	2
256	Calorie restriction-mediated restoration of hypothalamic signal transducer and activator of transcription 3 (STAT3) phosphorylation is not effective for lowering the body weight set point in IRS-2 knockout obese mice. Diabetology International, 2015, 6, 321-335.	0.7	2
257	Plasma glucose monitoring and the subsequent HbA1c control in patients with type 2 diabetes on a basal supported oral therapy regimen in real life: subanalysis of the ALOHA study: a 24-week, prospective, open-label, multicenter, observational study. Diabetology International, 2015, 6, 66-76.	0.7	2
258	Preceding psychological factors and calorie intake in patients with type 2 diabetes: investigation by ecological momentary assessment. BioPsychoSocial Medicine, 2019, 13, 20.	0.9	2
259	Efficacy and Safety of Fast-Acting Insulin Aspart in People with Type 1 Diabetes Using Carbohydrate Counting: A Post Hoc Analysis of Two Randomised Controlled Trials. Diabetes Therapy, 2019, 10, 1029-1041.	1.2	2
260	ADDITION-Europe: the first decade and beyond. Lancet Diabetes and Endocrinology,the, 2019, 7, 891-893.	5.5	2
261	Elucidating exercise-induced skeletal muscle signaling pathways and applying relevant findings to preemptive therapy for lifestyle-related diseases. Endocrine Journal, 2022, 69, 1-8.	0.7	2
262	Effect of a Multifactorial Intervention on Fracture in Patients With Type 2 Diabetes: Subanalysis of the J-DOIT3 Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2116-e2128.	1.8	2
263	A randomized, placeboâ€controlled trial to assess the efficacy and safety of sitagliptin in J apanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin. Diabetes, Obesity and Metabolism, 2021, 23, 1342-1350.	2.2	2
264	Effect of Branched-Chain Amino Acid Infusion on In-Hospital Mortality of Patients With Hepatic Encephalopathy and End-Stage Kidney Disease: A Retrospective Cohort Study Using a National Inpatient Database. , 2022, 32, 432-440.		2
265	A Machine Learning–Based Predictive Model to Identify Patients Who Failed to Attend a Follow-up Visit for Diabetes Care After Recommendations From a National Screening Program. Diabetes Care, 2022, 45, 1346-1354.	4.3	2
266	NFIA determines the cis-effect of genetic variation on Ucp1 expression in murinethermogenic adipocytes. IScience, 2022, 25, 104729.	1.9	2
267	Generation of highly specific vector-based shRNAi libraries directed against the entire human genome. , 2005, , 480-496.		1
268	The PREDICTIVETM Study: a multinational, prospective observational study to evaluate the safety and efficacy of insulin detemir treatment in patients with type 1 and 2 diabetes—data from the Japan cohort. Diabetology International, 2012, 3, 11-20.	0.7	1
269	Effects of beraprost sodium, an oral prostacyclin analog, on insulin resistance in patients with type 2 diabetes. Diabetology International, 2015, 6, 39-45.	0.7	1
270	Societal Marketing in the Treatment of Type 2 Diabetes Mellitus: A Longitudinal Questionnaire Survey for Michelin-Starred Restaurants in Japan. International Journal of Environmental Research and Public Health, 2019, 16, 636.	1.2	1

#	Article	IF	CITATIONS
271	Midlobular zone 2 hepatocytes: A gatekeeper of liver homeostasis. Cell Metabolism, 2021, 33, 855-856.	7.2	1
272	Genotype-Structure-Phenotype Correlations of Disease-Associated IGF1R Variants and Similarities to Those of INSR Variants. Diabetes, 2021, 70, 1874-1884.	0.3	1
273	Vascular endothelial growth factor (VEGF) activates Raf-1, mitogen-activated protein (MAP) kinases, and S6 kinase (p90rsk) in cultured rat cardiac myocytes. , 1998, 175, 239.		1
274	The 61st Annual Meeting of the Japan Endocrine Society Symposium Cellular Mechanism of Hormone Action Role of the Insulin Receptor Kinase Activity in Insulin Action. Nippon Naibunpi Gakkai Zasshi, 1988, 64, 1243-1249.	0.0	0
275	Approach to the Pathogenesis of Non-Insulin-Dependent Diabetes Mellitus by Gene Targeting Proceedings of the Japanese Society of Animal Models for Human Diseases, 1997, 13, 75-78.	0.1	Ο
276	Type 1 Diabetes Mellitus Associated with Vogt-Koyanagi-Harada Syndrome, Palmoplantar Pustulosis, and Hashimoto's Thyroiditis. The Journal of the Japanese Society of Internal Medicine, 2009, 98, 1369-1371.	0.0	0
277	Evi1 Is a Stem Cell-Specific Regulator of Self-Renewal Capacity In the Definitive Hematopoietic System. Blood, 2010, 116, 838-838.	0.6	0
278	Insulin-like Growth Factor I (IGF-I) Therapy in a Patient with Severe Insulin Resistance Syndrome. Clinical Pediatric Endocrinology, 1994, 3, 239-239.	0.4	0
279	The Effect of Hyperinsulinemia and Insulin Resistance on Atherosclerosis in Rats with Transplanted Pancreas and In Insulin Receptor Substrate-1 (IRS-1) Knockout Mouse. The Journal of Japan Atherosclerosis Society, 1997, 24, 505-508.	0.0	0
280	Elucidation of Pathogenesis and Development of Therapeutic Strategy of Type 2 Diabetes -Progress in the Thirty Years. The Journal of the Japanese Society of Internal Medicine, 2016, 105, 1543-1557.	0.0	0
281	Adiponectin Receptors AdipoRs Action Mechanisms and Clinical Application The Journal of the Japanese Society of Internal Medicine, 2016, 105, 1746-1752.	0.0	0
282	AdipoRon: An anti-diabetes and anti-aging drug. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY62-3.	0.0	0
283	The adiponectin receptor: Physiology and pharmacology. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, CL-30.	0.0	0
284	5. Patients with Diabetes Difficult to Manage and Their Countermeasures. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 1810-1818.	0.0	0
285	Long-Term Pancreas Allograft Survival in Simultaneous Pancreas-Kidney Transplantation by Era. Clinical Transplants, 2015, 31, 35-42.	0.2	0
286	Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study. Expert Opinion on Drug Safety, 2022, , .	1.0	0